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Abstract Meningiomas are common primary brain
tumors. However, they are often complicated by significant
peritumoral brain edema, which leads to surgery difficulties
and prolonged hospitalization. The aim of this study was to
evaluate the presence of mast cells and expression of
hypoxia inducible factor-1 (HIF-1) in correlation with the
grade of meningioma and presence of peritumoral brain
edema. Immunohistochemistry was performed with spe-
cific antibodies against tryptase (mast cells) and HIF-1 in
low grade meningiomas (estimated as G1) and high grade
meningiomas (estimated as G2 or G3). Peritumoral brain
edema observed in MRI was graded using Steinhoff clas-
sification. Tryptase expression was observed in 40.4 % low
grade meningiomas and in 90 % high grade cases; HIF-1 in
55.7 % low grade and in 84 % high grade meningiomas.
There was a statistically significant correlation between
HIF-1 and tryptase expression in both groups (p = 0.003).
Presence of peritumoral brain edema statistically correlated
with tryptase (p = 0.001) and HIF-1 expression
(p = 0.004). Mast cells as well as hypoxia are involved in
meningioma progression, and may be associated with the
formation of peritumoral brain edema leading to surgery
complication and recovery. Therefore, they may be useful
markers in predicting the clinical course of meningioma
cases.
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Introduction
Mast cells are multi-effector cells, however they are still
the least understood components of the immune system [1].
In recent decades, the importance and fascinating biology
of mast cells has been described in many physiological and
pathological conditions, but the role of mast cells in tumor
development and progression is still unknown [2]. Mast
cells (MCs) are often present in large amounts in the
stroma of different neoplasms, such as: mammary adeno-
carcinoma, colorectal adenocarcinoma, urothelial carci-
noma, neurofibroma or melanoma [3]. Much data
postulated that MCs may affect tumor development in few
different ways: by affecting tumor cells directly, by mod-
ulating the tumor microenvironment, or by activating other
inflammatory cells beneficial for tumor progression [3, 4].
The effect of that activity depends on the multiplicity of
molecules which are synthesized and secreted to the
extracellular matrix from MCs’ granules [5], such as:
platelet derived factor, colony stimuli factor, and nerve
growth factor [6]. Also histamine could affect tumor pro-
gression by inducing proliferation through H1 receptor and
suppressing the immune system via the H2 receptor. It was
discovered that histamine and tryptase concentrations
positively correlate with mast cell count in mammary
carcinomas [7].
It is also known that tumor growth and progression is
closely related to angiogenesis [5, 6]. Pathological angio-
genesis mainly depends on the release of specific growth
factors for endothelial cells, which may stimulate prolif-
eration of the host’s blood vessels. Some data suggest that
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activated MCs synthesize and secrete pro-angiogenic fac-
tors such as fibroblast growth factor-2 and vascular endo-
thelial growth factor (VEGF). There is high expression of
VEGF in MC accumulated around tumors [2, 4, 6].
There are many theories about brain tumor progression
and the presence of mast cells. It depends on the blood–
brain-barrier (BBB) [8, 9]. On the one hand, mast cells
surround endothelial cells and, under the normal condi-
tions, pericytes play the role of ‘‘gate keepers’’ of the BBB
[10]. MCs also have anatomical and functional connections
with neurons. On the other hand, acute stress can activate
MCs by corticotrophin-releasing hormone and leads to
inflammation development and increased BBB permeabil-
ity, which may be responsible for brain metastases [7, 10].
Peritumoral brain edema in primary brain tumors and in
metastases is a very serious complication associated with
surgery and postsurgical recovery. Pathological vessels
inside the tumor, without normal tight junctions, also lead
to an increase of peritumoral edema, which is often
observed in glioblastoma cases [8, 11, 12]. As a result, the
surrounding edematous brain tissue might be easily infil-
trated by neoplastic cells, resulting in tumor spreading.
Hypoxia-inducible factor-1 (HIF-1) is a transcriptional
factor which consists of two subunits; under hypoxic
conditions it may induce transcription of various genes
involved in tumor angiogenesis (like vascular endothelial
growth factor- VEGF), invasion (metalloproteinases), cell
survival (antiapoptotic proteins), and glucose metabolism
insulin growth factor receptor activation [12]. Overex-
pression of HIF-1 has been demonstrated in many common
human cancers and correlated with tumor grade and pro-
gression, including renal, colon, and glioblastoma [12].
However, the significance of HIF-1 expression especially
in high grade meningiomas is still unclear.
Almost 60 % of meningioma cases have peritumoral
brain edema, mostly vasogenic edema with disruption of
the BBB [8, 9, 13, 14]. Some of researchers suggest that
peritumoral brain edema, resulting in worse prognosis or
difficulties with total resection, is associated with hypoxia
and inflammatory cell infiltration [13–15].
Therefore, the aim of this study was to evaluate the
presence of mast cells, HIF-1 expression in association with
peritumoral brain edema in meningiomas of various grades.
Materials and methods
Peritumoral brain edema was evaluated in MRI by an
experienced radiologist and graded by Steinhoff classifi-
cation: 0—no signs of the edema; I- peritumoral brain
edema limited to 2 cm; II- peritumoral brain edema limited
to half of the hemisphere; III- more than half of the
hemisphere [16].
We studied 154 meningioma cases at the Department of
Neurosurgery Medical University of Bialystok
(2008–2012). All cases were diagnosed by a neuropathol-
ogist based on WHO classification (Lyon 2007). Evalua-
tion of mast cells presence and HIF-1 expression was
performed using immunohistochemical methods. Follow-
ing deparaffinization and rehydration, epitope retrieval was
carried out in Envision Flex Target Retrieval Solution
(DAKO) in high pH. Endogenous peroxidases were
blocked by incubating sections in methanol and 3 %
hydrogen peroxydase for 20 min. Next, slides were incu-
bated with a typical mast cell marker, tryptase. We used
monoclonal mouse anti-human mast cell tryptase (clone
AA1, DAKO) in 1:100 dilution at room temperature for
20 min. The complexes were visualized with EnVision
(DAKO) and DAB for 10 min. HIF-1 expression was
evaluated using goat monoclonal antibody against HIF-1
protein (Santa Cruz Biotechnology HIF-1a, sc-53546) in
1:100 dilution stored overnight in 4 C. Visualization
reagent EnVision (DAKO) was applied for 30 min fol-
lowed by DAB solution for 10 min. The slides were then
counterstained with hematoxylin and examined under a
light microscope. In order to avoid false evaluation,
immunohistochemical estimation of each protein expres-
sion was performed by two independent pathologists. The
intensity of immunostaining was evaluated in ten random
fields under 209 magnification. The results were expressed
as the percentage of cells with strong positive staining as
follows: B10 % positive cells- negative (-), between 11
and 50 % (?), and C51 % positive cells (??) [17].
Appropriate positive and negative controls were per-
formed. Negative controls were performed using a non-
immunized IgG replacing the primary antibody. Knowing
tryptase expression in skin mastocytosis, we used those
specimens as a positive control; for HIF-1 expression, renal
clear cell cancer specimens were used.
All the procedures were approved by the local bioethics
committee and conducted in accordance with institutional
guidelines in compliance with national and international
laws and guidelines.
Statistical analysis
Chi squared, Pearson’s correlation test, and Statistica 10.0
StatSoft software were used for statistical analysis. Values
of p \ 0.05 were considered statistically significant.
Results
In our present study, 104 tumors were diagnosed as low
grade meningioma (G1), 50 were estimated as high grade
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meningioma (G2 or G3). All cases were classified
according to WHO classification (Lyon 2007).
Peritumoral brain edema was observed in 103 out of 154
meningiomas (66.8 %). 57 cases presented small peritu-
moral brain edema limited to 2 cm (I Steinhoff classifi-
cation), 44 covered less than half of the hemisphere (II
Steinhoff classification), and only two presented extensive
peritumoral edema covering more than half of the hemi-
sphere (III Steinhoff classification) (Fig. 1). All patients
with II and III had longer recovery time (from 4 to
10 days) compared with patients with I or without perit-
umoral brain edema (from 3 to 7 days). Hospitalization
time in the neurosurgery department was on average
2–3 days longer compared with patients classified as grade
I meningiomas. After surgery, patients were admitted to the
radiotherapy department for further treatment.
Low grade meningiomas were diagnosed in 27 male
patients and in 77 female patients. Mean age in low grade
meningiomas was 54.5 years.
High grade meningiomas were diagnosed in 27 male and
in 23 female patients. Mean age was 52 years. The dif-
ferences between age and sex in both groups were statis-
tically significant (p = 0.003).
Tryptase expression in both examined groups
Tryptase expression was observed in 42 out of 104 low
grade meningioma cases (40.4 %). 17 out of all positive
specimens were estimated as (??) (Figs. 2, 3)—immu-
nostaining was strong and observed in more than 50 % of
neoplastic cells.
In high grade meningiomas, tryptase expression was
observed in 45 out of 50 cases (90 %), 6 out of 45 were
estimated as (??). Mast cells were observed not only next
to blood vessels, but also within the tumor (Fig. 4).
HIF-1 expression in both examined groups
HIF-1 expression was observed within the nucleus of
neoplastic cells.
In low grade meningiomas, HIF-1 immunostaining was
observed in 58 out of 104 cases (55.7 %) (Fig. 5).
In the high grade meningioma group, HIF-1 expres-
sion was observed in 42 out of 50 cases (84 %) (Figs. 3,
6).
When we compared the expression of the examined
marker with the degree of meningioma, we observed a
statistically significant cross-correlation between tryptase
Fig. 1 MRI scans showing peritumoral brain edema associated with meningioma, estimated (using Steinhoff classification) as grade II
Fig. 2 Tryptase expression in low grade meningioma Magn. 9100
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expression and HIF-1 expression in both histological
groups of meningiomas (Table 1) (p = 0.003).
In the low grade meningioma group, 25 out of 104 cases
were positive for HIF-1 and tryptase; in the high grade
meningioma group, 40 out of 50 cases presented positive
staining for HIF-1 and tryptase.
Correlation between tryptase, HIF-1 expression
and presence of peritumoral brain edema
We divided all the examined meningioma cases into 4
subgroups, using Steinhoff classification.
Tryptase expression was observed in: 33 out of 57
meningiomas with I Steinhoff classification of peritumoral
edema, 32 out of 44 meningiomas II Steinhoff classifi-
cation, 2 out of 2 meningiomas with III Steinhoff classi-
fication of peritumoral edema. This result was statistically
significant (p = 0.001) (Table 2).
HIF-1 expression was observed in 40 out of 57 menin-
giomas with I Steinhoff classification, in 32 out of 44 with
II Steinhoff classification, and in 2 out of 2 cases with III
Fig. 4 Intense tryptase expression in high grade meningioma
observed mainly next to the blood vessels Magn. 940, 9100
Fig. 5 HIF-1 expression in low grade meningioma Magn. 9200
Fig. 6 HIF-1 expression in high grade meningioma Magn. 940
Fig. 3 Low grade meningioma with patchy tryptase expression next
to the psammoma body Magn. 9200
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Steinhoff classification of peritumoral edema. The result
was also statistically significant (p = 0.004) (Table 3).
Discussion
Several recent studies have evaluated the mechanisms of
peritumoral brain edema, which may complicate diagnosis
and treatment of primary brain tumors and metastases [7,
8]. Damage to the BBB through the opening of tight
junctions probably plays a significant role in the forma-
tion of vasogenic brain edema, which was observed in
high grade glial tumors [8]. There are many studies
concerning the etiology of the peritumoral brain edema.
Our study focused on the influence of hypoxia and pres-
ence of mast cells in association with peritumoral brain
edema. It is known that hypoxia may increase secretion of
cytokines, including interleukins (Il-6), indirectly leading
to mast cell degranulation [18]. Also, HIF-1 contributes to
inflammatory functions in various components of the
innate immune system, like dendritic cells, mast cells or
epithelial cells [19].
Meningiomas are common primary brain tumors, but
data concerning correlation between grade of meningioma
and presence of peritumoral brain edema are inconclusive.
Transitional and meningotheliomatous subtypes of menin-
giomas are often associated with more severe grades of
edema [20]. Many authors have attempted to explain the
mechanisms of peritumoral brain edema occurrence. Klc
et al. [21] suggested that tenascin-extracellular matrix
glycoprotein may be responsible for anaplasia, tumor-
associated edema and VEGF expression in meningioma
cases. Schmid et al. [22] presented VEGF as a crucial
factor in angiogenesis in meningiomas, indirectly associ-
ated with peritumoral brain edema formation. Recently, it
was observed that abnormal expression of occludins, which
are normally observed in tight endothelial junctions in the
BBB, may be responsible for peritumoral brain edema [23,
24]. Also, the expression of aquaporin-4 is correlated with
peritumoral brain edema [25]. Mattei et al. [26] observed








Low grade meningioma (G1) n = 104 p = 0.003
HIF-1 (-) 29 27.1 11 10.7 6 5.8
HIF-1 (?) 32 31.1 14 13.6 10 9.6
HIF-1 (??) 1 1.0 0 0.0 1 1.0
High grade meningioma (G2 or G3) n = 50
HIF-1 (-) 3 6.0 5 10.0 0 0.0
HIF-1 (?) 2 4.0 34 68.0 5 10
HIF-1 (??) 0 0.0 0 0.0 1 2.0
Table 2 Grade of peritumoral brain edema (Steinhoff classification) in correlation with tryptase expression









(-) 31 20.1 % 24 15.6 % 12 7.8 % 0 0.0 % p = 0.001
(?) 17 11.1 % 24 15.6 % 24 15.6 % 0 0.0 %
(??) 3 1.9 % 9 5.8 % 8 5.2 % 2 1.3 %
Table 3 HIF-1 expression in correlation with the grade of peritumoral brain edema









(-) 25 16.3 % 17 11.1 % 12 7.8 % 0 0.0 % p = 0.004
(?) 25 16.3 % 40 26.0 % 31 20.1 % 1 0.6 %
(??) 1 0.6 % 0 0.0 % 1 0.6 % 1 0.6 %
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that the degree of peritumoral brain edema is associated
with the histological grading of meningiomas. However,
the results presented by Osawa et al. [27] showed that only
unusual types of meningiomas, such as angiomatous,
microcystic or secretory, are associated with peritumoral
brain edema.
Our results show a statistically significant association
between HIF-1 expression, tryptase expression, and the
presence of peritumoral brain edema. More than half
meningiomas with II peritumoral brain edema and all cases
with III were positive (statistically significant) for HIF-1
and tryptase expression. Also statistically significant corre-
lation was observed between presence of mast cells (tryptase
expression) and HIF-1 expression according to meningioma
grade. High grade meningiomas (estimated as G2 or G3)
were positive for both proteins, tryptase and HIF-1.
Our results suggest that hypoxia stimulates HIF-1
overexpression as well as mast cell activation, which may
lead to blood-brain barrier breakage, resulting in peritu-
moral brain edema. This theory might be supported by the
studies of Kaynar et al. and Jannsen et al. who observed
elevated HIF-1 expression in meningiomas, suggesting that
other consequences of hypoxia, not only known VEGF
activation, are also observed in meningiomas [28–30]. Kan
et al. [9] observed a correlation between grade of menin-
gioma and peritumoral brain edema. High grade histology
meningioma appeared to be more common in association
with edema. Yoo et al. [31] observed in 50 % of all
examined meningiomas regions of hypoxia, assessed by
expression of carbonic anhydrase 9 (CA9), and this
expression was significantly associated with high-grade
histology. Also, among low grade meningiomas, CA9
expression tended to be more common in recurrent tumors.
Spanberger et al. [32] who examined the expression of
HIF-1 in single brain metastases in association with perit-
umoral brain edema, obtained different results. They con-
cluded that patients with small peritumoral edema have
shorter survival times and their tumors are characterized by
more brain-invasive growth, lower HIF-1 expression, and
less angiogenic activity. Our study presents that high grade
meningiomas with significant peritumoral brain edema are
very rich in mast cells. Tirakotai et al. [14] described cases
of secretory meningiomas with numerous mast cells within
the tumors, suggesting that peritumoral brain edema, which
was observed in those cases, may be associated with the
accumulation and activation of mast cells. Similarly, Bo
et al. [13] found numerous inflammatory cells, like lym-
phocytes, macrophages and mast cells in menigiomas,
suggesting that inflammatory cells deserve to be taken into
consideration as predictive factors of recurrence and bio-
logical aggressiveness of meningiomas. Osawa et al. [27]
observed that angiomatous, microcystic, secretory and
lymphocyte-rich meningiomas are often associated with
higher peritumoral brain edema. Also, Schober et al. [33]
found increased numbers of mast cells in microcystic for-
mations in meningiomas that had high peritumoral brain
edema.
Despite that low grade meningiomas are mostly benign
types of brain tumors, mortality associated with surgery is
variable in literature, ranging from 4 to 23 % in the early
postoperative period [34]. Presence of peritumoral brain
edema is associated with prolonged hospitalization and
with postoperative complications, such as intracranial
hematoma or intracranial hypertension [34]. Therefore,
recognition of the mechanisms responsible for peritumoral
brain edema occurrence is very important to improve
treatment and later convalescence.
Our study showed that mast cells, which are important
in inflammatory processes, as well as HIF-1 may be
involved in the formation of peritumoral brain edema,
worse prognosis, and more aggressive phenotype of
meningioma. Therefore, evaluation of those two markers
may be useful in identifying meningiomas with a poten-
tially worse postoperative clinical course.
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